Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

PHASE3CompletedINTERVENTIONAL
Enrollment

513

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

February 28, 2015

Conditions
CachexiaNon-Small Cell Lung Cancer
Interventions
DRUG

Anamorelin HCl

DRUG

Placebo

Trial Locations (72)

Unknown

Corona

Fountain Valley

Fullerton

Glendale

La Jolla

Riverside

Washington D.C.

Orange City

Quincy

Indianapolis

Louisville

Boston

Lake Success

Durham

Cleveland

Sylvania

West Reading

Charleston

Falls Church

Prairiewood

Adelaide

East Bentleigh

Victoria

Brest

Lesnoy

Minsk

Antwerp

Brussels

Genk

Ghent

Liège

Edmonton

Sault Ste. Marie

Toronto

Montreal

Benešov

Brno

Hlučín

Liberec

Nymburk

Lyon

Villejuif

Großhansdorf

Halle

Budapest

Kassai

Beersheba

Petach Tikvah

Tel Litwinsky

Ẕerifin

Piacenza

Bydgoszcz

Grudziądz

Katowice

Krakow

Lodz

Lublin

Szczecin

Warsaw

Krasnodar

Moscow

Saint Petersburg

Yekaterinburg

Belgrade

Kamenitz

Ljubljana

Barcelona

Seville

Valencia

Dnipropetrovsk

Kharkiv

Kyiv

All Listed Sponsors
lead

Helsinn Therapeutics (U.S.), Inc

INDUSTRY

NCT01395914 - Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) | Biotech Hunter | Biotech Hunter